User profiles for R. Kleemann

Robert Kleemann

TNO, Dept. Metabolic Health Research, Leiden, The Netherlands
Verified email at tno.nl
Cited by 16725

Cytokines and atherosclerosis: a comprehensive review of studies in mice

R Kleemann, S Zadelaar, T Kooistra - Cardiovascular research, 2008 - academic.oup.com
In the past few years, inflammation has emerged as a major driving force of atherosclerotic
lesion development. It is now well-established that from early lesion to vulnerable plaque …

Mouse models for atherosclerosis and pharmaceutical modifiers

S Zadelaar, R Kleemann, L Verschuren… - … , and vascular biology, 2007 - Am Heart Assoc
Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that
work synergistically to promote lesion development. The ability to develop preventive and …

[HTML][HTML] Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease

H Lue, R Kleemann, T Calandra, T Roger… - Microbes and …, 2002 - Elsevier
… Bernhagen and R. Kleemann, unpublished). … We are grateful to our colleagues for
participation in the studies and their helpful discussions: R. Bucala, H. Brunner, A. …

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

…, P Ghezzi, R Kleemann, SR McColl, R Bucala… - Nature medicine, 2007 - nature.com
The cytokine macrophage migration inhibitory factor (MIF) plays a critical role in inflammatory
diseases and atherogenesis. We identify the chemokine receptors CXCR2 and CXCR4 as …

Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1

R Kleemann, A Hausser, G Geiger, R Mischke… - Nature, 2000 - nature.com
Kleemann, R. et al. Disulfide analysis reveals a role for macrophage migration … Angel
for the pBAT-c-Jun and pRSV-c-Jun constructs; and R. Bucala for … Robert Kleemann

[HTML][HTML] Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology

…, JH Lindeman, R Stoop, LM Havekes, R Kleemann… - PloS one, 2014 - journals.plos.org
Background and aims The recently developed histological scoring system for non-alcoholic
fatty liver disease (NAFLD) by the NASH Clinical Research Network (NASH-CRN) has been …

Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase

R Kleemann, A Kapurniotu, RW Frank… - Journal of molecular …, 1998 - Elsevier
The molecular mechanism of action of macrophage migration inhibitory factor (MIF), a cytokine
with a critical role in the immune and inflammatory response, has not yet been identified. …

Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis

…, G Fraedrich, HE Schaefer, S Dimmeler, R Kleemann… - Circulation, 2002 - Am Heart Assoc
Background— Atherosclerosis is a chronic inflammatory response of the arterial wall to injury.
Macrophage migration inhibitory factor (MIF), a cytokine with potent inflammatory functions…

Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models

R Kleemann, L Verschuren, M Morrison, S Zadelaar… - Atherosclerosis, 2011 - Elsevier
OBJECTIVE: Polyphenols such as quercetin may exert several beneficial effects, including
those resulting from anti-inflammatory activities, but their impact on cardiovascular health is …

Neuroimmune cardiovascular interfaces control atherosclerosis

…, S Steffens, J Pelisek, HH Eckstein, R Kleemann… - Nature, 2022 - nature.com
Atherosclerotic plaques develop in the inner intimal layer of arteries and can cause heart
attacks and strokes 1 . As plaques lack innervation, the effects of neuronal control on …